Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib with Rituximab and Bendamustine in iNHL
NCT02576275Phase 3Withdrawn
- Sponsor
- Secura Bio
- Start
- Dec 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Indolent Non-Hodgkin Lymphoma (INHL) comparing Duvelisib + Rituximab + Bendamustine with Placebo + Rituximab + Bendamustine (2 arms). Primary endpoint: Progression-Free Survival up to 78 months. Planned start Dec 2015; status: withdrawn.
02
Drugs
duvelisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT02576275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576275.